Erythropoietin isoforms
DC CAFC
First Claim
Patent Images
1. An isolated biologically active erythropoietin isoform having a single isoelectric point and having a specific number of sialic acids per molecule, said number selected from the group consisting of 1-14, and said isoform being the product of the expression of an exogenous DNA sequence in a non-human eucaryotic host cell.
0 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Erythropoietin isoforms having a specific number of sialic acids per erythropoietin molecule are disclosed. Also disclosed are mixtures of such isoforms, pharmaceutical compositions containing such isoforms or mixtures thereof and methods of obtaining the erythropoietin isoforms.
186 Citations
31 Claims
- 1. An isolated biologically active erythropoietin isoform having a single isoelectric point and having a specific number of sialic acids per molecule, said number selected from the group consisting of 1-14, and said isoform being the product of the expression of an exogenous DNA sequence in a non-human eucaryotic host cell.
- 13. Erythropoietin consisting essentially of erythropoietin molecules having a single specific number of sialic acids per molecule, said number selected from the group consisting of 1-14, and said molecules being the product of the expression of an exogenous DNA sequence in a non-human eucaryotic host cell.
-
24. A method of preparing erythropoietin molecules having a predetermined number of sialic acids per molecule said number selected from the group consisting of 1-14, comprising applying material containing erythropoietin to an ion exchange column and selectively eluting said molecules from the column.
-
25. A method of preparing erythropoietin molecules having a predetermined number of sialic acids per molecule said number selected from the group consisting of 1-14, comprising applying material containing erythropoietin to a chromatofocusing column and selectively eluting said molecules from the column.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeAmgen Inc.
-
Original AssigneeAmgen Inc.
-
InventorsStrickland, Thomas Wayne
-
Primary Examiner(s)Walsh, Stephen G.
-
Application NumberUS08/334,882Time in Patent Office1,524 DaysField of Search530/395, 530/397, 530/416, 530/412, 514/8, 435/69.4, 204/182.9US Class Current514/7.7CPC Class CodesA61K 38/00 Medicinal preparations cont...C07K 14/505 Erythropoietin [EPO]
